Core Insights - Gilead Sciences has entered licensing agreements with six pharmaceutical companies to produce a low-cost version of lenacapavir for HIV prevention in 120 low-and lower-middle-income countries [1][3] - Lenacapavir has shown promising results in late-stage studies, achieving primary efficacy goals and demonstrating superior efficacy compared to Truvada [2] - Gilead aims to support access to lenacapavir through a royalty-free licensing program and will supply the drug at no profit until generic manufacturers can meet demand [3][5] Licensing Agreements - The selected companies for manufacturing lenacapavir include Dr. Reddy's Laboratories, Emcure, Eva Pharma, Ferozsons Laboratories, Hetero, and Mylan [1] - The agreements cover lenacapavir for both prevention and treatment of multi-drug-resistant HIV [3] - Gilead's choice of partners was based on their experience in producing high-quality generics and sterile injectable medicines [3] Market Strategy - Gilead plans to register lenacapavir in 18 countries that account for approximately 70% of the HIV burden in the licensed regions [5] - The countries targeted for registration include Botswana, Kenya, Nigeria, South Africa, and others [5] - Gilead has previously enabled access to affordable treatments for HIV and other diseases through partnerships, distributing over 30 million treatments in low-and middle-income countries [5] Clinical Development - Two pivotal studies, PURPOSE 1 and PURPOSE 2, have shown that lenacapavir, administered twice a year, is more effective than the daily oral dose of Truvada [2] - Gilead plans to submit global regulatory filings for lenacapavir by the end of 2024 [2] - Year-to-date, Gilead's shares have increased by 4.6%, outperforming the industry average decline of 1.5% [2]

Company Performance - Gilead Sciences closed at $83.79, with a -0.24% change from the previous session, underperforming the S&P 500's gain of 0.25% [1] - The stock has increased by 9.13% over the past month, contrasting with the Medical sector's loss of 1.51% and the S&P 500's gain of 1.65% [1] - The upcoming earnings report is projected to show earnings per share (EPS) of $1.66, a decrease of 27.51% year-over-year, with expected quarterly revenue of $6.98 billion, down 0.98% from the previous year [1] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $3.78 per share, representing a -43.75% change from the prior year, while revenue is expected to be $27.63 billion, reflecting a +1.9% change [2] - Recent revisions to analyst forecasts are important as they indicate short-term business trends, with positive revisions seen as a favorable sign for the company's outlook [2] Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 22.23, which is higher than the industry average of 21.46, suggesting it is trading at a premium [3] - The company has a PEG ratio of 2.91, compared to the industry average PEG ratio of 2.21, indicating a higher valuation relative to projected earnings growth [3] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 80, placing it in the top 32% of over 250 industries [4] - The Zacks Industry Rank measures the strength of industry groups, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [4]

Gilead Sciences, Inc. (GILD) announced upbeat results from an interim analysis of a second late-stage study evaluating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV.Results showed that lenacapavir, administered twice yearly, not only reduced HIV infections by 96% but also demonstrated superiority to Gilead’s daily HIV pill Truvada.The strong results validated lenacapavir’s potential to prevent HIV. Investors were impressed and GILD stock was ...

In drug development, solid performance in large-scale clinical trials is crucial.There was some good news in the clinical sphere for Gilead Sciences (GILD 2.74%) on Thursday, and this drove its stock price up by almost 3% that trading session. A late-stage clinical trial of an investigational drug yielded encouraging initial results, hence the rise. In comparison, the S&P 500 index inched up by 0.8% on the day.HIV drug does well in the labGilead's news was that its second phase 3 trial of HIV drug lenacapav ...

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday.The positive phase three trial data on Lenacapavir sets the stage for likely approval by the U.S. Food and Drug Administration for HIV prevention."Now that we have a comprehensive dataset across multiple study populations, Gilead will work urgently with regulatory, government, public health and community partners to ensure that, if approved, we can deliver twice-yearly lenacapavir for PrEP worldwide, ...

Gilead Sciences, Inc. (NASDAQ:GILD) Baird Global Healthcare Conference September 10, 2024 10:50 PM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Skorney - Baird Brian Skorney [Starts abruptly] biotech analysts here. [Technical Difficulty] to have presenting with us next, Gilead Sciences. Thanks for coming today. We really appreciate it. Maybe just to kick things off, I'll kind of ask the general question to give a broad overview of what Gilead does and ...

Gilead Sciences, Inc. (NASDAQ:GILD) Baird Global Healthcare Conference September 10, 2024 10:50 PM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Skorney - Baird Brian Skorney [Starts abruptly] biotech analysts here. [Technical Difficulty] to have presenting with us next, Gilead Sciences. Thanks for coming today. We really appreciate it. Maybe just to kick things off, I'll kind of ask the general question to give a broad overview of what Gilead does and ...

Gilead Sciences, Inc. (NASDAQ:GILD) Wells Fargo 2024 Healthcare Conference September 4, 2024 11:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Good morning, my name is Mohit Bansal. I'm one of the biopharma analyst here at Wells Fargo. And this is my third year hosting it. And I think... Andrew Dickinson Third year's [indiscernible]. Mohit Bansal So thank you, Andy, for joining us today. Andrew Dickinson Thank you ...

Gilead Sciences, Inc. (NASDAQ:GILD) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 12:20 PM ET Company Participants Daniel O'Day - Charman & CEO Andrew Dickinson - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morg ...

Gilead Sciences, Inc. (NASDAQ:GILD) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 12:20 PM ET Company Participants Daniel O'Day - Charman & CEO Andrew Dickinson - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morg ...